Effect of Hormone Replacement Therapy on Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials

Yang, Dicheng; Li, Jing; Yuan, Zhongxiang; Liu, Xu
May 2013
PLoS ONE;May2013, Vol. 8 Issue 5, p1
Academic Journal
Background: Hormone replacement therapy (HRT) is widely used to controlling menopausal symptoms and prevent adverse cardiovascular events. However, the benefit and risk of HRT on cardiovascular outcomes remains controversial. Methodology and Principal Findings: We systematically searched the PubMed, EmBase, and Cochrane Central Register of Controlled Trials databases for obtaining relevant literature. All eligible trials reported on the effects of HRT on cardiovascular outcomes. We did a random effects meta-analysis to obtain summary effect estimates for the clinical outcomes with use of relative risks calculated from the raw data of included trials. Of 1903 identified studies, we included 10 trials reporting data on 38908 postmenopausal women. Overall, we noted that estrogen combined with medroxyprogesterone acetate therapy as compared to placebo had no effect on coronary events (RR, 1.07; 95%CI: 0.91–1.26; P = 0.41), myocardial infarction (RR, 1.09; 95%CI: 0.85–1.41; P = 0.48), stroke (RR, 1.21; 95%CI: 1.00–1.46; P = 0.06), cardiac death (RR, 1.19; 95%CI: 0.91–1.56; P = 0.21), total death (RR, 1.06; 95%CI: 0.81–1.39; P = 0.66), and revascularization (RR, 0.95; 95%CI: 0.83–1.08; P = 0.43). In addition, estrogen therapy alone had no effect on coronary events (RR, 0.93; 95%CI: 0.80–1.08; P = 0.33), myocardial infarction (RR, 0.95; 95%CI: 0.78–1.15; P = 0.57), cardiac death (RR, 0.86; 95%CI: 0.65–1.13; P = 0.27), total mortality (RR, 1.02; 95%CI: 0.89–1.18; P = 0.73), and revascularization (RR, 0.77; 95%CI: 0.45–1.31; P = 0.34), but associated with a 27% increased risk for incident stroke (RR, 1.27; 95%CI: 1.06–1.53; P = 0.01). Conclusion/Significance: Hormone replacement therapy does not effect on the incidence of coronary events, myocardial infarction, cardiac death, total mortality or revascularization. However, it might contributed an important role on the risk of incident stroke.


Related Articles

  • Link between varenicline and cardiovascular events questioned.  // Reactions Weekly;5/12/2012, Issue 1401, p1 

    The article discusses research on the link between varenicline use and cardiovascular events. It references a study by J. J. Prochaska et al published in the May 4, 2012 issue of the "British Medical Journal." A meta-analysis of the drug's randomised controlled trials revealed no significant...

  • Meta-Regression Analyses to Explain Statistical Heterogeneity in a Systematic Review of Strategies for Guideline Implementation in Primary Health Care. Unverzagt, Susanne; Peinemann, Frank; Oemler, Matthias; Braun, Kristin; Klement, Andreas // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    This study is an in-depth-analysis to explain statistical heterogeneity in a systematic review of implementation strategies to improve guideline adherence of primary care physicians in the treatment of patients with cardiovascular diseases. The systematic review included randomized controlled...

  • Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. Sohaib, S.M. Afzal; Chen, Zhongbo; Whinnett, Zachary I.; Bouri, Sonia; Dickstein, Kenneth; Linde, Cecilia; Hayes, David L.; Manisty, Charlotte H.; Francis, Darrel P. // European Journal of Heart Failure;Dec2013, Vol. 15 Issue 12, p1419 

    Aims Prognostic benefit from CRT compared with controls is well established. Symptomatic response rates, however, are controversial and have never been systematically evaluated with standard subtraction of control rates to establish the incremental symptomatic response effect of CRT pacing....

  • Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. Dawson, Marliese Y.; Michalak, Erin E.; Waraich, Paul; Anderson, J. Ellen; Lam, Raymond W. // BMC Family Practice;2004, Vol. 5, p19 

    Background: A primary goal of acute treatment for depression is clinical remission of symptoms. Most meta-analyses of remission rates involve randomized controlled trials (RCTs) using patients from psychiatric settings, but most depressed patients are treated in primary care. The goal of this...

  • Cognitive--behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Beltman, Matthijs W.; Oude Voshaar, Richard C.; Speckens, Anne E. // British Journal of Psychiatry;Jul2010, Vol. 197 Issue 1, p11 

    Background Meta-analyses on psychological treatment for depression in individuals with a somatic disease are limited to specific underlying somatic diseases, thereby neglecting the generalisability of the interventions. Aims To examine the effectiveness of cognitive-behavioural therapy (CBT) for...

  • TMS Improves Anxiety Symptoms in Depression. Parry, Nicola // MD Conference Express;Jun2014, Vol. 14 Issue 8, p15 

    This article presents data from a meta-analysis of randomized controlled trials in transcranial magnetic stimulation (TMS) among depressed patients. The results showed that TMS appears effective in treating anxiety symptoms in patients with depression.

  • Self-Guided Psychological Treatment for Depressive Symptoms: A Meta-Analysis. Cuijpers, Pim; Donker, Tara; Johansson, Robert; Mohr, David C.; Straten, Annemieke van; Andersson, Gerhard // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Background: A number of trials have examined the effects of self-guided psychological intervention, without any contact between the participants and a therapist or coach. The results and sizes of these trials have been mixed. This is the first quantitative meta-analysis, aimed at organizing and...

  • Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials. Li, Xianbin; Tang, Yilang; Wang, Chuanyue // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Objective: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. Methods: Population: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related...

  • National Heart Foundation hypertension guideline update - 2015. Medley, T.; Wilson, J. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS128 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics